Iovance Biotherapeutics shares are trading higher after Wells Fargo maintained an Overweight rating on the stock and raised its price target from $22 to $25.
Portfolio Pulse from Benzinga Newsdesk
Iovance Biotherapeutics' stock price increased following Wells Fargo's decision to maintain an Overweight rating and raise its price target from $22 to $25.
March 01, 2024 | 8:56 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Iovance Biotherapeutics' shares rose after Wells Fargo maintained an Overweight rating and increased the price target from $22 to $25.
The increase in Iovance Biotherapeutics' stock price is directly attributed to Wells Fargo's positive analyst rating and raised price target. Such endorsements from reputable financial institutions often lead to increased investor confidence and demand for the stock, driving up its price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100